Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 19, 2022

De-Escalated Neoadjuvant Chemotherapy for Early TNBC

Clinical Cancer Research


Additional Info

Clinical Cancer Research
De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial
Clin. Cancer Res 2022 Jul 07;[EPub Ahead of Print], O Gluz, U Nitz, C Kolberg-Liedtke, A Prat, M Christgen, S Kuemmel, MP Mohammadian, D Gebauer, R Kates, L Paré, EM Grischke, H Forstbauer, M Braun, M Warm, J Hackmann, C Uleer, B Aktas, C Schumacher, R Wuerstlein, M Graeser, E Pelz, K Jóźwiak, C Zu Eulenburg, HH Kreipe, N Harbeck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading